ProQR Therapeutics Analyst Ratings
H.C. Wainwright Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Raises Target Price to $10
Chardan Capital Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Announces Target Price $4
Raymond James Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Raises Target Price to $14
ProQR Therapeutics Analyst Ratings
ProQR Therapeutics Analyst Ratings
ProQR Therapeutics Analyst Ratings
ProQR Therapeutics Analyst Ratings
Raymond James Maintains Outperform on ProQR Therapeutics, Lowers Price Target to $4
Chardan Capital Upgrades ProQR Therapeutics to Buy, Announces $2 Price Target
ProQR Therapeutics Analyst Ratings
Buy Rating for ProQR Therapeutics: Robust RNA-Editing Patent Portfolio, Promising Preclinical Candidates, and Strong Financial Position
Citigroup Maintains Buy on ProQR Therapeutics, Lowers Price Target to $1.8
ProQR Therapeutics Analyst Ratings
ProQR Therapeutics Analyst Ratings
ProQR Therapeutics Analyst Ratings
Chardan Assigns New Price Target of $2 to ProQR Therapeutics, Keeps Neutral Rating
Cantor Fitzgerald Adjusts Price Target on ProQR Therapeutics to $4.50 From $5, Maintains Overweight Rating
HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target
HC Wainwright Raises Price Target on ProQR Therapeutics to $5 From $1.50, Maintains Buy Rating